JP4688678B2 - 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用 - Google Patents

抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用 Download PDF

Info

Publication number
JP4688678B2
JP4688678B2 JP2005510086A JP2005510086A JP4688678B2 JP 4688678 B2 JP4688678 B2 JP 4688678B2 JP 2005510086 A JP2005510086 A JP 2005510086A JP 2005510086 A JP2005510086 A JP 2005510086A JP 4688678 B2 JP4688678 B2 JP 4688678B2
Authority
JP
Japan
Prior art keywords
seq
cancer
protein
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005510086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536891A5 (https=
JP2007536891A (ja
Inventor
冰 朱
Original Assignee
北京沙東生物技術有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京沙東生物技術有限公司 filed Critical 北京沙東生物技術有限公司
Publication of JP2007536891A publication Critical patent/JP2007536891A/ja
Publication of JP2007536891A5 publication Critical patent/JP2007536891A5/ja
Application granted granted Critical
Publication of JP4688678B2 publication Critical patent/JP4688678B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2005510086A 2003-11-03 2003-11-03 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用 Expired - Lifetime JP4688678B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/000928 WO2005042744A1 (en) 2003-11-03 2003-11-03 A recombinant protein with cancer suppression action, its encoding gene and use

Publications (3)

Publication Number Publication Date
JP2007536891A JP2007536891A (ja) 2007-12-20
JP2007536891A5 JP2007536891A5 (https=) 2010-02-12
JP4688678B2 true JP4688678B2 (ja) 2011-05-25

Family

ID=34529378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005510086A Expired - Lifetime JP4688678B2 (ja) 2003-11-03 2003-11-03 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用

Country Status (11)

Country Link
US (1) US7666989B2 (https=)
EP (1) EP1688498B1 (https=)
JP (1) JP4688678B2 (https=)
CN (1) CN100549175C (https=)
AT (1) ATE501256T1 (https=)
AU (1) AU2003280921B2 (https=)
BR (1) BRPI0318594B8 (https=)
CA (1) CA2544473C (https=)
DE (1) DE60336353D1 (https=)
NZ (1) NZ547274A (https=)
WO (1) WO2005042744A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
WO2009131191A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 メタスチン誘導体およびその用途
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
CN103534273B (zh) * 2011-09-16 2020-05-12 北京沙东生物技术有限公司 环化变构trail/apo2l及其编码基因与应用
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
AU708239B2 (en) * 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
KR20010019100A (ko) * 1999-08-25 2001-03-15 황규언 인간 유래 세포소멸인자 ｔｒａｉｌ의 결정화에 의한 3차원 구조
US6900185B1 (en) * 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
KR100436089B1 (ko) * 2000-07-06 2004-06-14 설대우 분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
CN1205335C (zh) * 2001-11-30 2005-06-08 中国人民解放军第二军医大学 肿瘤凋亡诱导配体基因、基因表达蛋白及其制备方法

Also Published As

Publication number Publication date
WO2005042744A1 (en) 2005-05-12
EP1688498B1 (en) 2011-03-09
CN100549175C (zh) 2009-10-14
ATE501256T1 (de) 2011-03-15
HK1089788A1 (zh) 2006-12-08
BRPI0318594B1 (pt) 2017-12-26
US20080280821A1 (en) 2008-11-13
DE60336353D1 (de) 2011-04-21
CA2544473C (en) 2013-08-13
EP1688498A4 (en) 2007-06-20
BR0318594A (pt) 2006-10-17
BRPI0318594B8 (pt) 2021-05-25
JP2007536891A (ja) 2007-12-20
CN1860229A (zh) 2006-11-08
NZ547274A (en) 2009-02-28
AU2003280921B2 (en) 2007-09-13
EP1688498A1 (en) 2006-08-09
AU2003280921A1 (en) 2005-05-19
CA2544473A1 (en) 2005-05-12
US7666989B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
KR100767554B1 (ko) 암 억제 유전자 더블유티1의 생산물에 기초한 암항원
EP3047024B1 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
KR102314231B1 (ko) 전립선 암 치료용 조성물
JP4688678B2 (ja) 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
JP7830450B2 (ja) 修飾されたｉｌ－２分子及びその用途
US8071716B2 (en) Thymus-specific protein
RU2333221C2 (ru) Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
JP4780540B2 (ja) サバイビン由来癌抗原ペプチド
JP5956580B2 (ja) Ｔｒａｉｌ／ａｐｏ２ｌの円順列変異形を含む融合タンパク質、コーディング遺伝子およびそれらの使用
KR100863060B1 (ko) 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
CN119874872B (zh) 一种mita铰链区突变多肽及其在自身免疫性疾病中的应用
CN100410273C (zh) 抑癌蛋白及其基因和用途
KR20110086460A (ko) 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
HK1089788B (en) A recombinant protein with cancer suppression action, its encoding gene and use
WO2025049019A1 (en) Variants of human programmed cell death protein (pd-1)
ZA200604478B (en) A recombinant protein with cancer suppression action, its encoding gene and uses thereof
MXPA06004932A (en) A recombinant protein with cancer suppression action, its encoding gene and use
JP2007197452A (ja) 感受性疾患剤
Fiers et al. TNF-Mediated Cytotoxicity: Mechanism and Regulation

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110208

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110215

R150 Certificate of patent or registration of utility model

Ref document number: 4688678

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140225

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term